Stanford phd candidate Calvin schmidt posts about investing opportunities in synthetic biology. Available for consulting on potential investments in this area.

Calvin Schmidt Synthetic Biology Index: December Update

Performance overview

Value at beginning of month: $135,877.90

Value at end of month: $112,858.19

Month over month change: -16.94%

Total IRR: 6.23%

Related indices, monthly change

NASDAQ: -10.18%

IVV (iShares Core S&P 500): -9.70%

IBB (iShares NASDAQ Biotechnology Index): -13.07%

MXI (iShares Global Materials): -4.24%

VEGI (iShares MSCI Global Agriculture Producers): -7.06%

ICLN (iShares Clean Energy): -7.32%

Individual performances

g5899.png

The general market had the worst December since the Great Depression, and synthetic biology companies were not immune from the downward pressure. In fact, they underperformed the market, falling 17% to end the year down around 18%. The only company that gained value was Dyadic, while the worst performing company was Ziopharm, who lost half their value this month. Most of the other companies were down about 15% to 30%. Hopefully, January is a better month for the CSSBI!

Changes made to index

Added Autolus and Sutro Biopharma.

You can view the index here.

Allocation as of December 30, 2018

g4165.png

2018 SynBio Venture Review

Calvin Schmidt Synthetic Biology Index: November Update